Late Morbidity, Mortality Down for Survivors of Childhood ALL
THURSDAY, Aug. 20, 2020 -- Contemporary survivors of childhood acute lymphoblastic leukemia (ALL) have reduced late morbidity and mortality, according to a study published online July 24 in the Journal of Clinical Oncology.
Stephanie B. Dixon,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2020 Category: Pharmaceuticals Source Type: news
Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news
Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
FRIDAY, July 31, 2020 -- Survivors of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) may experience late effects, with a high incidence of subsequent endocrine disease and cardiac disease, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news
A spin-off to develop therapies for leukaemia based on CAR-T, by Josep Carreras Institute
(Josep Carreras Leukaemia Research Institute) Invivo Ventures, CDTI-Innvierte (Spanish Ministry of Industry) and the Josep Carreras Foundation have established a first round of funding of 3,050,000. OCI will carry out three projects, the most advanced of which is a CAR-T CD1a (OCI-1) project for the treatment of cortical T-cell acute lymphoblastic leukemia (coT-ALL), a subtype of leukaemia that mainly affects children and which has a poor prognosis if patients do not respond to standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2020 Category: International Medicine & Public Health Source Type: news
What Are Some Pediatric Oncological Emergencies?
Discussion
Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
TUESDAY, June 30, 2020 -- Diets high in antioxidant-rich foods may cut the risk of developing bacterial infections or mucositis during the first phase of acute lymphoblastic leukemia (ALL) treatment in pediatric patients, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news
Treating leukaemia more effectively
(Goethe University Frankfurt) Acute lymphoblastic leukaemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine. The drug has not been successful, however, with B-ALL, a subtype resembling B-lymphocytes. This has puzzled oncologists sinced the 1980's. Now, an international research team headed by Goethe University and the University of Kent has discovered the reason: B-ALL cells contain the enzyme SAMHD1, which deactivates the drug. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 24, 2020 Category: Biology Source Type: news
What if child maltreatment were childhood leukemia? Lessons from the halls of the hospital - Babcock P.
This article examines lessons that can be applied to prevention, research, training, and clinical treatment in child welfare from analogous experiences in combatting childhood acute lymphoblastic leukemia (ALL). Since the 1960s, childhood cancer researcher... (Source: SafetyLit)
Source: SafetyLit - June 9, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL
A universal chimeric antigen receptor (CAR) T-cell therapy produced responses in adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) in initial findings from an ongoing study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo
A new analysis of 8300 patients with ALL undergoing chemotherapy revealed that secondary ALL is common, and the prolonged long-term survival rate is 30% to 50%. Women had a lower risk of death than men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
First-in-Human Trial of TruUCAR GC027 in Relapsed/Refractory T-Cell ALL Announced
The first-in-human clinical trial for TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia was announced by Gracell Biotechnologies. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Discovered the physiological mechanisms underlying the most common pediatric Leukemia
(Josep Carreras Leukaemia Research Institute) Researchers from the Josep Carreras Leukaemia Research Institute unveil the mechanisms that lead to hyperdiploid Acute Lymphoblastic Leukemia, Hyper D-ALL, the most common pediatric B-cell Leukaemia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2020 Category: Biology Source Type: news
Study reveals properties of cells fated to relapse in acute lymphoblastic leukemia
(St. Jude Children's Research Hospital) Researchers have found that genetically defined subpopulations of leukemia cells present at diagnosis have distinct characteristics that lead to relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 3, 2020 Category: Cancer & Oncology Source Type: news
Isolated Extramedullary Relapse in Acute Lymphoblastic Leukemia: What Can We Do Before and After Transplant?
The case of a 43-year-old male with a history of B-cell acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Santiago Riviello-Goya, MD, Aldo A. Acosta-Medina, MD, Sergio I. Inclan-Alarcon, MD, Sofia Garcia-Miranda, MD, Christianne Bourlon, MD, MHSc Source Type: news
Joseph Wynne, MD, Discusses Developments in the Field of Acute Lymphoblastic Leukemia
The ALL expert spoke about new research in the field and how it has changed the landscape for this disease. (Source: CancerNetwork)
Source: CancerNetwork - January 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
